Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data.
OBJECTIVE
The different clinical subtypes of multiple sclerosis (MS) may reflect underlying differences in affected neuroanatomic regions. Our aim was to analyze the effectiveness of jointly using the inferior subolivary medulla oblongata volume (MOV) and the cross-sectional area of the corpus callosum in distinguishing patients with relapsing-remitting multiple sclerosis (RRMS), secondary-progressive multiple sclerosis (SPMS), and primary-progressive multiple sclerosis (PPMS).


METHODS
We analyzed a cross-sectional dataset of 64 patients (30 RRMS, 14 SPMS, 20 PPMS) and a separate longitudinal dataset of 25 patients (114 MR imaging examinations). Twelve patients in the longitudinal dataset had converted from RRMS to SPMS. For all images, the MOV and corpus callosum were delineated manually and the corpus callosum was parcellated into 5 segments. Patients from the cross-sectional dataset were classified as RRMS, SPMS, or PPMS by using a decision tree algorithm with the following input features: brain parenchymal fraction, age, disease duration, MOV, total corpus callosum area and areas of 5 segments of the corpus callosum. To test the robustness of the classification technique, we applied the results derived from the cross-sectional analysis to the longitudinal dataset.


RESULTS
MOV and central corpus callosum segment area were the 2 features retained by the decision tree. Patients with MOV >0.94 cm(3) were classified as having RRMS. Patients with progressive MS were further subclassified as having SPMS if the central corpus callosum segment area was <55.12 mm(2), and as having PPMS otherwise. In the cross-sectional dataset, 51/64 (80%) patients were correctly classified. For the longitudinal dataset, 88/114 (77%) patient time points were correctly classified as RRMS or SPMS.


CONCLUSIONS
Classification techniques revealed differences in affected neuroanatomic regions in subtypes of multiple sclerosis. The combination of central corpus callosum segment area and MOV provides good discrimination among patients with RRMS, SPMS, and PPMS.
Sampat
M P
MP
Center for Neurological Imaging, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Berger
A M
AM
Healy
B C
BC
Hildenbrand
P
P
Vass
J
J
Meier
D S
DS
Chitnis
T
T
Weiner
H L
HL
Bakshi
R
R
Guttmann
C R G
CR
D019412:Anatomy, Cross-Sectional / Q000379:methods*; D001284:Atrophy / Q000473:pathology; D001921:Brain / Q000473:pathology*; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000473:pathology*; D009413:Nerve Fibers, Myelinated / Q000473:pathology*
J Neuroimaging. 2005;15(4 Suppl):94S-102S
16385022
Neurology. 1996 Apr;46(4):907-11
8780061
J Neurol Neurosurg Psychiatry. 2007 Apr;78(4):375-80
17119006
Ann Neurol. 2001 Jul;50(1):121-7
11456302
Neurology. 1999 Jul 13;53(1):139-48
10408550
Curr Opin Neurol. 2003 Jun;16(3):259-65
12858060
J Neurol Sci. 1995 Oct;132(2):222-7
8543952
J Neurol. 1996 Jul;243(7):502-5
8836938
Mult Scler. 2004 Aug;10(4):392-7
15327035
J Magn Reson Imaging. 2006 Apr;23(4):473-6
16521094
Mult Scler. 2007 Jan;13(1):41-51
17294610
Nat Clin Pract Neurol. 2006 Jan;2(1):34-44
16932519
Neuron. 2006 Oct 5;52(1):61-76
17015227
J Magn Reson Imaging. 2002 Feb;15(2):203-9
11836778
Cereb Cortex. 1999 Oct-Nov;9(7):712-21
10554994
J Neurol Neurosurg Psychiatry. 2006 Jan;77(1):51-5
16361592
Neurobiol Aging. 2001 Jul-Aug;22(4):603-11
11445261
Med Image Anal. 2000 Mar;4(1):43-55
10972320
J Neurol. 2003 Mar;250(3):307-15
12638021
Arch Neurol. 2004 Jul;61(7):1081-6
15262739
Neuroimage. 2006 Sep;32(3):989-94
16854598
Brain. 1989 Jun;112 ( Pt 3):799-835
2731030
Ann Neurol. 2005 Dec;58(6):840-6
16283615
Neurology. 2004 Jul 27;63(2):335-9
15277630
Brain. 2002 Aug;125(Pt 8):1676-95
12135961
J Neurol. 2003 Mar;250(3):287-92
12638018
Brain. 2003 Aug;126(Pt 8):1734-44
12805100
Neurology. 1993 Dec;43(12):2632-7
8255468
J Neurol Neurosurg Psychiatry. 1999 Mar;66(3):323-30
10084530
Arch Neurol. 2002 Feb;59(2):275-80
11843699
AJNR Am J Neuroradiol. 2008 Sep;29(8):1465-70
18556361
J Neurol. 2000 Feb;247(2):97-101
10751110
Arch Neurol. 2001 Jan;58(1):105-11
11176943
Neurology. 2007 Sep 18;69(12):1213-23
17875909
NeuroRx. 2004 Apr;1(2):284-94
15717029
Brain. 2001 Sep;124(Pt 9):1813-20
11522583
J Magn Reson Imaging. 2004 Jul;20(1):1-7
15221802
Ann Neurol. 2000 Mar;47(3):391-5
10716264
Lancet Neurol. 2006 Feb;5(2):158-70
16426992
Lancet Neurol. 2007 Oct;6(10):903-12
17884680
Neuroradiology. 1994 Jul;36(5):364-8
7936176
J Neurol Neurosurg Psychiatry. 2006 Sep;77(9):1036-9
16793860
Autoimmun Rev. 2006 Oct;5(8):532-6
17027888
Neurology. 1998 Jul;51(1):234-8
9674808
AJNR Am J Neuroradiol. 2003 Mar;24(3):410-8
12637291
Brain. 1996 Jun;119 ( Pt 3):701-8
8673483
J Neuroimmunol. 2007 Mar;184(1-2):37-44
17196667
AJNR Am J Neuroradiol. 2006 Jun-Jul;27(6):1165-76
16775258
J Neurol Neurosurg Psychiatry. 2007 May;78(5):491-6
17028118
J Magn Reson Imaging. 1999 Apr;9(4):509-18
10232508
Hum Brain Mapp. 2009 Aug;30(8):2656-66
19067325
Arch Neurol. 2005 Dec;62(12):1859-62
16344343
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):437-41
17673493
Brain. 2004 May;127(Pt 5):1009-18
15047586